These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28747013)

  • 1. Estrogen can restore Tamoxifen sensitivity in breast cancer cells amidst the complex network of resistance.
    Mansouri S; Farahmand L; Hosseinzade A; Eslami-S Z; Majidzadeh-A K
    Biomed Pharmacother; 2017 Sep; 93():1320-1325. PubMed ID: 28747013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
    Berstein LM; Yue W; Wang JP; Santen RJ
    Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
    Jordan VC; Fan P; Abderrahman B; Maximov PY; Hawsawi YM; Bhattacharya P; Pokharel N
    Discov Med; 2016 May; 21(117):411-27. PubMed ID: 27355337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
    Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells.
    Yue W; Fan P; Wang J; Li Y; Santen RJ
    J Steroid Biochem Mol Biol; 2007; 106(1-5):102-10. PubMed ID: 17616457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen Resistance: Emerging Molecular Targets.
    Rondón-Lagos M; Villegas VE; Rangel N; Sánchez MC; Zaphiropoulos PG
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.
    Gutteridge E; Agrawal A; Nicholson R; Cheung KL; Robertson J; Gee J
    Int J Cancer; 2010 Apr; 126(8):1806-1816. PubMed ID: 19739079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
    McDaniel RE; Maximov PY; Jordan VC
    Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66.
    Farahmand L; Mansouri S; Jafarbeik-Iravani N; Teymourzadeh A; Majidzadeh-A K
    Recent Pat Anticancer Drug Discov; 2018; 13(3):302-307. PubMed ID: 29512469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
    Planas-Silva MD; Waltz PK; Kilker RL
    J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen resistance in breast cancer: elucidating mechanisms.
    Dorssers LC; Van der Flier S; Brinkman A; van Agthoven T; Veldscholte J; Berns EM; Klijn JG; Beex LV; Foekens JA
    Drugs; 2001; 61(12):1721-33. PubMed ID: 11693462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.
    Hatkevich T; Ramos J; Santos-Sanchez I; Patel YM
    Exp Cell Res; 2014 Oct; 327(2):331-9. PubMed ID: 24881818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
    Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
    Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer.
    Abderrahman B; Maximov PY; Curpan RF; Hanspal JS; Fan P; Xiong R; Tonetti DA; Thatcher GRJ; Jordan VC
    Mol Pharmacol; 2020 Oct; 98(4):364-381. PubMed ID: 32788222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
    Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
    Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.